Medication persistence for psoriatic arthritis in a Brazilian real-world setting

Página do item simplificado
dc.creatorMichael Ruberson Ribeiro da Silva
dc.creatorJéssica Barreto Ribeiro dos Santos
dc.creatorAlessandra Maciel Almeida
dc.creatorAlexander Itria
dc.creatorAdriana Maria Kakehasi
dc.creatorJuliana Alvares Teodoro
dc.creatorFrancisco de Assis Acurcio
dc.date.accessioned2023-07-18T16:46:21Z
dc.date.accessioned2025-09-08T23:07:02Z
dc.date.available2023-07-18T16:46:21Z
dc.date.issued2019
dc.identifier.doihttps://doi.org/10.4155/fsoa-2018-0101
dc.identifier.issn2056-5623
dc.identifier.urihttps://hdl.handle.net/1843/56584
dc.languagepor
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofFuture Science OA
dc.rightsAcesso Aberto
dc.subjectAgentes anti-reumaticos
dc.subjectMedicamentos
dc.subject.otherAntirheumatic agents
dc.subject.otherMedication persistence
dc.subject.otherPsoriatic arthritis
dc.titleMedication persistence for psoriatic arthritis in a Brazilian real-world setting
dc.typeArtigo de periódico
local.citation.issue2
local.citation.volume5
local.description.resumoAim: To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional syntheticdisease-modifyingantirheumaticdrugs[csDMARDs])antirheumaticagentsforpsoriaticarthritisand their associated factors. Methods: A historical cohort was developed. Persistence and associated factors wereevaluatedat6and12months.Results:Atotalof161patientswereincluded.Theanti-TNFtreatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4vs35.6%;p<0.05).Fromanti-TNFs,adalimumabandetanerceptpresentedsimilarpersistence,along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence withregardtoanti-TNFagentswerefemalesexanduseofinfliximab.Conclusion:Anti-TNFagentsareimportanttherapeuticalternativesand presentlowerratesofdiscontinuationascomparedwithcsDMARDs. Lay abstract: Conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and anti-TNF agents were included in the Brazilian National Health System in 2009, yet were not previously the target of evaluations in a Brazilian context. Persistence, that is the time between starting and discontinuing the drug, is a proxy of effectiveness and safety for antirheumatic agents. This study evaluated medication persistence and relevant factors associated with it. Patients using infliximab showed a lower medication persistence when compared with adalimumab and etanercept. The medication persistence with anti-TNF agents was higher when compared with csDMARDs. Female sex and infliximab were predictors of medication non-persistence.
local.identifier.orcidhttps://orcid.org/0000-0003-2550-7249
local.identifier.orcidhttps://orcid.org/0000-0002-5528-0658
local.identifier.orcidhttps://orcid.org/0000-0003-0138-9401
local.identifier.orcidhttps://orcid.org/0000-0001-7500-0230
local.identifier.orcidhttps://orcid.org/0000-0001-9411-7493
local.identifier.orcidhttps://orcid.org/0000-0002-0210-0721
local.identifier.orcidhttps://orcid.org/0000-0002-5880-5261
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE FARMÁCIA SOCIAL
local.publisher.departmentMED - DEPARTAMENTO DE APARELHO LOCOMOTOR
local.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICA
local.publisher.initialsUFMG
local.url.externahttps://www.future-science.com/doi/10.4155/fsoa-2018-0101

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Medication persistence for psoriatic arthritis in a Brazilian real-world setting.pdf
Tamanho:
183.85 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG